Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:56:48 ON 07 MAR 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:56:58 ON 07 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2008 HIGHEST RN 1006950-27-1
DICTIONARY FILE UPDATES: 6 MAR 2008 HIGHEST RN 1006950-27-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\erich.str





chain nodes :
7 8 9 16 17 18 21
ring nodes :
1 2 3 4 5 6 10 11 12 13 14
chain bonds :
3-7 5-17 7-8 8-9 9-10 11-21 13-16 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-14 11-12 12-13 13-14
exact/norm bonds :
3-7 5-17 7-8 8-9 9-10 10-11 10-14 11-12 11-21 12-13 13-14 13-16 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 10 :

G1:O,S,N

G2:Ph,Ak

G3:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 16:Atom 17:CLASS 18:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N
G2 Ph,Ak
G3 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:57:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 346 TO 1054
PROJECTED ANSWERS: 93 TO 587

L2 17 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:57:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 752 TO ITERATE

100.0% PROCESSED 752 ITERATIONS 318 ANSWERS
SEARCH TIME: 00.00.01

L3 318 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 16:57:26 ON 07 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Mar 2008 VOL 148 ISS 11
FILE LAST UPDATED: 6 Mar 2008 (20080306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 24 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:284433 CAPLUS
DOCUMENT NUMBER: 146:337575
TITLE: Arylacetic acids and related compounds as PPAR modulators and their preparation, pharmaceutical compositions and use in the treatment of PPAR-mediated diseases
INVENTOR(S): Lin, Jack; Womack, Patrick; Lee, Byunghun; Shi, Shenghua; Zhang, Chao; Artis, Dean R.; Ibrahim, Prabha N.; Wang, Weiru; Zuckerman, Rebecca
PATENT ASSIGNEE(S): Plexxikon, Inc., USA
SOURCE: PCT Int. Appl., 239pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007030567	A2	20070315	WO 2006-US34764	20060906
WO 2007030567	A3	20070621		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-715214P P 20050907
US 2006-789387P P 20060405
OTHER SOURCE(S): MARPAT 146:337575
GI



I



II

AB Compds. of formula I that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ, are described. Compds. of formula I wherein X is CO2H na derivs., CONH2 and derivs., and carboxylic acid isostere; W is bond, (un)substituted C1-2 alkylamino, (un)substituted C1-2 alkoxy, (un)substituted C1-3 alkylene, (un)substituted ethenylene; R1 and R2 are independently H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted lower alkynyl, etc.; R3 is (un)substituted alkyl; L is O, S, NH and derivs., CO, CS, SO, SO2, CONH and derivs., etc.; and their pharmaceutically acceptable salts, prodrugs, tautomers, and isomers, thereof are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their PPARα, PPARγ, and PPARδ activity. From the assay, it was determined that several compds. exhibited EC50 values of less than or equal to 1 μM against at least one of the PPARα, PPARγ or PPARδ.

IT 929092-92-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of arylacetic acids and related compds. useful in prophylaxis and treatment of diseases - mediated by PPARα, PPARγ and PPARδ receptors)

RN 929092-92-2 CAPLUS

CN Benzeneacetic acid, 3-butoxy-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:510320 CAPLUS
DOCUMENT NUMBER: 145:27708
TITLE: Preparation of (hydroxybenzyl)(hydroxyimino)butyric acids as PPARγ and PPARα agonists
INVENTOR(S): Kim, Geun Tae; Koh, Jong Sung; Han, Hee Oon; Kim, Seung Hae; Kim, Kyoung-Hee; Chung, Hee-Kyung; Hong, Sung Woon; Lee, Chang-Seok; Koo, Ki Dong; Yim, Hyeon Joo; Hur, Gwong-Cheung; Kim, Hye Jin; Park, Ok Ku; Lee, Hyun Mi; Woo, Sung Ho
PATENT ASSIGNEE(S): LG Life Sciences, Ltd., S. Korea
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006057505	A1	20060601	WO 2005-KR3943	20051122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 2006058631	A	20060530	KR 2005-111521	20051122
PRIORITY APPLN. INFO.:			KR 2004-97343 A	20041125

OTHER SOURCE(S): CASREACT 145:27708; MARPAT 145:27708
GI



AB Title compds. represented by the formula I [wherein A = (un)substituted oxazolyl, thiazolyl, 1,2,4-oxadiazolyl, etc.; m = 0 or 1; n = 1 or 2; G = H; and pharmaceutically acceptable salts or isomers thereof] were prepared as PPARγ and PPARα agonist. For example, reaction of 2-(5-methyl-2-phenyloxazol-4-yl)ethyl methanesulfonate with Me

4-(4-hydroxyphenyl)-3-(propoxyimino)butanoate (56%), and followed by hydrolysis (72%), gave II. I showed accelerating effectively the activity of human PPARγ and PPARα. Thus, I and their pharmaceutical compns. are useful as PPARγ and PPARα agonists for the treatment of diabetes mellitus or implications associated with, or inflammation.

IT 888707-85-5P, 3-(Ethoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoic acid 888707-87-7P, 3-(Propoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoic acid 888707-94-6P, (E)-3-(Ethoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoic acid 888707-96-8P, (Z)-3-(Ethoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoic acid 888708-07-4P, (E)-3-(Propoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoic acid 888708-09-6P, (Z)-3-(Propoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hydroxybenzyl)(hydroxyimino)butyric acid derivs. as PPARγ and PPARα agonist)

RN 888707-85-5 CAPLUS
CN Benzenebutanoic acid, β-(ethoxyimino)-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 888707-87-7 CAPLUS
CN Benzenebutanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-(propoxyimino)- (CA INDEX NAME)



RN 888707-94-6 CAPLUS
CN Benzenebutanoic acid, β-(ethoxyimino)-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (βE)- (CA INDEX NAME)

Double bond geometry as shown.



RN 888707-96-8 CAPLUS
CN Benzenebutanoic acid, β-(ethoxyimino)-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (βZ)- (CA INDEX NAME)

Double bond geometry as shown.



RN 888708-07-4 CAPLUS
CN Benzenebutanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-(propoxyimino)-, (βE)- (CA INDEX NAME)

Double bond geometry as shown.



RN 888708-09-6 CAPLUS
CN Benzenebutanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-(propoxyimino)-, (βZ)- (CA INDEX NAME)

Double bond geometry as shown.



IT 888707-84-4P, Methyl 3-(ethoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoate 888707-86-6P, Methyl 3-(propoxyimino)-4-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]butanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (hydroxybenzyl)(hydroxyimino)butyric acid derivs. as PPARγ and PPARα agonist)
RN 888707-84-4 CAPLUS

CN Benzenebutanoic acid, β-(ethoxyimino)-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 888707-86-6 CAPLUS
CN Benzenebutanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-(propoxyimino)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:395278 CAPLUS
DOCUMENT NUMBER: 142:447209
TITLE: Preparation of α-hydroxyimino-β-benzylpropanoate derivatives as PPARγ and PPARα agonists for the treatment of diabetes mellitus and inflammation diseases
INVENTOR(S): Kim, Geun Tae; Koh, Jong Sung; Han, Hee Oon; Kim, Seung Hae; Kim, Kyoung-Hee; Chung, Hee-Kyung; Kim, Yeon Chul; Kim, Misun; Koo, Ki Dong; Yim, Hyeon Joo; Hur, Gwong-Cheung; Lee, Sun Hwa; Lee, Chang-Seok; Woo, Sung Ho
PATENT ASSIGNEE(S): LG Life Sciences Ltd., S. Korea
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040127	A1	20050506	WO 2004-KR2729	20041027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005040746	A	20050503	KR 2004-86055	20041027
PRIORITY APPLN. INFO.:			KR 2003-75037 A	20031027
			KR 2003-75041 A	20031027
			KR 2003-75046 A	20031027

OTHER SOURCE(S): CASREACT 142:447209; MARPAT 142:447209
GI



I



II

AB Title compds. I [wherein A = (un)substituted (cyclo)alkyl, (hetero)aryl, amine, amido, alkoxy, sulfonyl or sulfanyl; B, D, X = H or alkyl; E = H, alkyl or aryl; and pharmaceutically acceptable nontoxic salts, physiol. hydrolyzable esters, hydrates, solvates, isomers or prodrugs thereof] were prepared as agonists of peroxisome proliferator-activated receptor gamma (PPARγ) and alpha (PPARα). For example, II was synthesized via etherification of the corresponding phenol (preparation given) with methanesulfonate ester of the pyrazolemethanol (preparation given) in 40% yield. I were found to be very effective for accelerating the activity of PPARγ and PPARa with EC50 values of <1 μM and <1000 nM (<100 nM for II), resp. Therefore, I are useful for treating or preventing PPARγ- and PPARa-related diseases, such as diabetes mellitus, its complications and inflammation.

IT 851180-35-3P, 3-[[(4-Fluorobenzyl)oxy]imino]-2-[3-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]butyric acid 851180-36-4P, 3-[[(4-Fluorobenzyl)oxy]imino]-2-[3-[2-[5-methyl-2-(thiophen-2-yl)oxazol-4-yl]ethoxy]benzyl]butyric acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonist; preparation of (hydroxyimino)benzylpropanoates as PPARγ and PPARα agonists)

RN 851180-35-3 CAPLUS

CN Benzenepropanoic acid, α-[1-[[(4-fluorophenyl)methoxy]imino]ethyl]-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 851180-36-4 CAPLUS

CN Benzenepropanoic acid, α-[1-[[(4-fluorophenyl)methoxy]imino]ethyl]-3-[2-[5-methyl-2-(2-thienyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

F

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:283476 CAPLUS
DOCUMENT NUMBER: 142:355258
TITLE: Preparation of azole compounds containing phenylacetic acid moiety as PPARδ agonists
INVENTOR(S): Kusuda, Shinya; Nakayama, Yoshisuke; Tajima, Hisao; Sakamoto, Takahiko
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005028453	A1	20050331	WO 2004-JP14137		20040921
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004274337	A1	20050331	AU 2004-274337		20040921
CA 2539554	A1	20050331	CA 2004-2539554		20040921
EP 1666472	A1	20060607	EP 2004-773449		20040921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004014580	A	20061107	BR 2004-14580		20040921
CN 1882553	A	20061220	CN 2004-80033842		20040921
NO 2006001281	A	20060622	NO 2006-1281		20060321
IN 2006CN00975	A	20070615	IN 2006-CN975		20060321
MX 2006PA03205	A	20060623	MX 2006-PA3205		20060322
US 2007105868	A1	20070510	US 2006-572937		20060322
PRIORITY APPLN. INFO.:			JP 2003-330616	A	20030922
			JP 2004-231546	A	20040806
			WO 2004-JP14137	W	20040921

OTHER SOURCE(S): MARPAT 142:355258
GI



I



II



III

AB Title compds. I [R1, R2 = H, alkyl, etc.; R3 = optionally substituted alkyl with halo, etc.; R4 = H, alkyl; R5, R6 = H, alkyl; further detail on R5, R6 is provided.; X = S, O, etc.; ring A = optionally substituted cyclic group] were prepared For example, reaction of compound II, e.g., prepared from 4-(trifluoromethyl)piperidine·HCl in 5 steps, with 2-fluoro-3-hydroxyphenylacetic acid Me ester under Mitsunobu condition followed by hydrolysis using aqueous NaOH afforded compound III. The exemplified compound III exhibited 1.23 fold increase for PPARδ at 1.0 μM. Compds. I are claimed useful as PPARδ agonists for the treatment of hyperlipidemia, obesity. Formulations are given.

IT 848943-21-5P 848943-48-6P 848943-66-8P
848943-67-9P 848943-68-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azole compds. containing phenylacetic acid moiety as PPAR agonists for treatment of hyperlipidemia, obesity)

RN 848943-21-5 CAPLUS

CN Benzeneacetic acid, 3-[2-[5-ethyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]-4-methyl-, methyl ester (CA INDEX NAME)



RN 848943-48-6 CAPLUS
CN Benzeneacetic acid, 2-fluoro-3-[2-[5-methyl-2-[4-(trifluoromethyl)-1-piperidinyl]-4-thiazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 848943-66-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-4-methyl-, methyl ester (CA INDEX NAME)



RN 848943-67-9 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-[4-(2-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 848943-68-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(3-furanyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-4-methyl-, methyl ester (CA INDEX NAME)



IT 848943-22-6P 848943-23-7P 848943-24-8P
848943-25-9P 848943-26-0P 848943-27-1P
848943-28-2P 848943-29-3P 848943-30-6P
848943-31-7P 848943-32-8P 848943-33-9P
848943-34-0P 848943-35-1P 848943-36-2P
848943-37-3P 848943-38-4P 848943-39-5P
848943-40-8P 848943-41-9P 848943-42-0P
848943-43-1P 848943-44-2P 848943-45-3P
848943-46-4P 848943-47-5P 848943-49-7P
848943-50-0P 848943-51-1P 848943-52-2P
848943-53-3P 848943-54-4P 848943-55-5P
848943-56-6P 848943-57-7P 848943-58-8P
848943-59-9P 848943-60-2P 848943-61-3P
848943-62-4P 848943-63-5P 848943-64-6P
848943-65-7P 848943-69-1P 848943-70-4P
848943-71-5P 848943-72-6P 848943-73-7P
848943-74-8P 848943-75-9P 848943-76-0P
848943-77-1P 848943-78-2P 848943-79-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole compds. containing phenylacetic acid moiety as PPAR agonists for treatment of hyperlipidemia, obesity)

RN 848943-22-6 CAPLUS

CN Benzeneacetic acid, 3-[2-[5-ethyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-23-7 CAPLUS

CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(trifluoromethyl)-1-piperidinyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-24-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-propyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-25-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-26-0 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-propyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-27-1 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-28-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-29-3 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-(1-methylethyl)-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-30-6 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-pentyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-31-7 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-phenyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-32-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-33-9 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-34-0 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-35-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-(1-methylethyl)-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-36-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-(2,2,2-trifluoroethyl)-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-37-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-propyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-38-4 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-propyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-39-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-butyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-40-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-butyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-41-9 CAPLUS
CN Benzeneacetic acid, 4-ethyl-3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-42-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-43-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-propyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-44-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-propyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-45-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-(1-methylethyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-46-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-(1-methylethyl)-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-47-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-ethyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-49-7 CAPLUS
CN Benzeneacetic acid, 2-fluoro-3-[2-[5-methyl-2-[4-(trifluoromethyl)-1-piperidinyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-50-0 CAPLUS
CN Benzeneacetic acid, 3-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-51-1 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-(4-phenyl-1-piperidinyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-52-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-53-3 CAPLUS
CN Benzeneacetic acid, 2-fluoro-3-[2-[5-methyl-2-(4-phenyl-1-piperidinyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-54-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-phenyl-1-piperazinyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-55-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(4-chlorophenyl)-1-piperazinyl]-5-methyl-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-56-6 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(4-methylphenyl)-1-piperazinyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-57-7 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(1,3-dihydro-2H-isoindol-2-yl)-5-methyl-4-thiazolyl]ethoxy]-2-fluoro- (CA INDEX NAME)



RN 848943-58-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(4-chlorophenyl)-1-piperazinyl]-5-methyl-4-thiazolyl]ethoxy]-2-fluoro- (CA INDEX NAME)



RN 848943-59-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(4-chlorophenyl)-1-piperazinyl]-5-methyl-4-thiazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-60-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(4-chlorophenyl)-1-piperidinyl]-5-methyl-4-thiazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-61-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-5-methyl-4-thiazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-62-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-5-methyl-4-thiazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-63-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(4-fluorophenyl)-1-piperidinyl]-5-methyl-4-thiazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-64-6 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-(4-phenyl-1-piperazinyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-65-7 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-[4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-69-1 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-[4-(2-pyridinyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-70-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(3-furanyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-71-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-72-6 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(3'-fluoro[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-73-7 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-[4-(2-thienyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-74-8 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-methyl-2-[4-(3-thienyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-75-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(2-furanyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-76-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(2-furanyl)phenyl]-5-(1-methylethyl)-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-77-1 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[5-(1-methylethyl)-2-[4-(2-thienyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 848943-78-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4'-methoxy[1,1'-biphenyl]-4-yl)-5-(1-methylethyl)-4-oxazolyl]ethoxy]-4-methyl- (CA INDEX NAME)



RN 848943-79-3 CAPLUS
CN Benzeneacetic acid, 4-methyl-3-[2-[2-(4'-methyl[1,1'-biphenyl]-4-yl)-5-(1-methylethyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1037096 CAPLUS
DOCUMENT NUMBER: 142:23512
TITLE: Preparation of N-acyl proline derivatives and related nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
INVENTOR(S): Ksander, Gary Michael; Vedananda, Thalaththani Ralalage
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103995	A1	20041202	WO 2004-EP5434	20040519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004240754	A1	20041202	AU 2004-240754	20040519
CA 2525764	A1	20041202	CA 2004-2525764	20040519
EP 1638963	A1	20060329	EP 2004-739269	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010779	A	20060627	BR 2004-10779	20040519
CN 1795193	A	20060628	CN 2004-80014021	20040519
JP 2007501263	T	20070125	JP 2006-529884	20040519
US 2006135593	A1	20060622	US 2005-556988	20051115
MX 2005PA12465	A	20060130	MX 2005-PA12465	20051118
IN 2005CN03050	A	20070727	IN 2005-CN3050	20051118
NO 2005006056	A	20060217	NO 2005-6056	20051220
KR 2008007519	A	20080121	KR 2008-700342	20080107
PRIORITY APPLN. INFO.:			US 2003-472067P P	20030520
			WO 2004-EP5434 W	20040519
			KR 2005-722001 A3	20051118

OTHER SOURCE(S): MARPAT 142:23512
GI



I



II

AB The invention relates to pharmacol. agents I [R1 is H, (un)substituted alkyl, aryl, heteroaryl, aralkyl or cycloalkyl; R2 is H, OH, oxo, (un)substituted alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy, alkylthio, arylthio or aralkylthio; R3 is H; or R2 and R3 combine to form a bond, a 5- to 7-membered ring or (un)substituted benzo; R4 is H or R42 is a bond; X is methylene, alkylidene, O, S, NH, alkyl- or arylimino; R, R' are independently H, halo, (un)substituted alkyl, alkoxy, aralkyl or heteroaralkyl or R and R' attached to adjacent carbon atoms combine to form an (un)substituted fused 5- to 6-membered aromatic or heteroarom. ring; X is Z-(CH2)1-8-Q-W, where Z is a bond, O, S, SO, SO2 or CONR5 (R5 is H, alkyl or aralkyl), Q is a bond, O(CH2)0-8, S(CH2)0-8, CONR6 [R6 is H, (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl], etc., and W is cycloalkyl, aryl, heterocyclyl, aralkyl or heteroaralkyl; or W and R6 combine to form a 8- to 12-membered bicyclic ring] and related 2-indolecarboxylic and 2-quinolinecarboxylic acid derivs. which bind to peroxisome proliferator-activated receptors (PPARs) and thus are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Four example illustrate the synthesis of compds. of the invention via acylation, etherification, and other reactions. Pyrrolidinecarboxylic acid derivative II shows an EC50 of about 3 nM in the PPARα receptor binding assay and an EC50 of about 1800 nM in the PPARγ receptor binding assay.

IT 799854-79-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-acyl proline derivs. and related nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors)

RN 799854-79-8 CAPLUS

CN D-Proline, 1-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:101148 CAPLUS
DOCUMENT NUMBER: 140:163867
TITLE: Preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivatives as antidiabetic agents
INVENTOR(S): Wickens, Philip; Cantin, Louis-David; Chuang, Chih-Yuan; Dai, Miao; Hentemann, Martin F.; Kumarasinghe, Ellalahewage; Liang, Sidney X.; Lowe, Derek B.; Shelekhin, Tatiana E.; Wang, Yamin; Zhang, Chengzhi; Zhang, Hai-Jun; Zhao, Qian
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011446	A1	20040205	WO 2003-US23342	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003263814	A1	20040216	AU 2003-263814	20030725
PRIORITY APPLN. INFO.:			US 2002-399095P	P 20020726
			WO 2003-US23342	W 20030725

OTHER SOURCE(S): MARPAT 140:163867
GI



I



II

AB Title compds., e.g., I [X = O, S; n = 1-3; R1 = carboxy, carboxamide, alkylamino, etc.; R2-3 = H, F, alkyl; R4-6 = H, alkyl; R7 = H, alkoxy, OH, etc.; R9 = H, Br, Cl, I, alkyl, etc.; R10 = H, OSO2CF3, etc.; R11 = H, alkyl, etc.; R12 = naphthyl, pyridyl, etc.] are prepared For instance, Et (S)-[5-hydroxy-2,3-dihydro-1H-inden-1-yl]acetate (preparation given) is coupled to 4-chloromethyl-5-methyl-2-phenyloxazole (preparation given; DMF, K2CO3, 3 h, 80°) to give II. I are useful in the treatment of diseases such as diabetes, diabetes-related disorders, obesity, hyperlipidemia and cardiovascular diseases.

IT 652980-85-3P, Ethyl 3-[2-methoxy-3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoate 652980-86-4P, 3-[2-Methoxy-3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)

RN 652980-85-3 CAPLUS

CN Benzenepropanoic acid, 2-methoxy-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 652980-86-4 CAPLUS

CN Benzenepropanoic acid, 2-methoxy-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:41231 CAPLUS
DOCUMENT NUMBER: 140:111429
TITLE: Preparation of substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T. W.; Chen, Sean; Devasthale, Pratik; Ding, Charles Z.; Herpin, Timothy F.; Wu, Shung; Zhang, Hao; Wang, Wei; Ye, Xiang-Yang
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 543 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004665	A2	20040115	WO 2003-US22149	20030702
WO 2004004665	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003259131	A1	20040123	AU 2003-259131	20030702
JP 2005536494	T	20051202	JP 2004-520148	20030702
EP 1656368	A2	20060517	EP 2003-763485	20030702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004063700	A1	20040401	US 2003-616365	20030708
US 7279485	B2	20071009		
NO 2005000077	A	20050203	NO 2005-77	20050106
US 2007287713	A1	20071213	US 2007-779319	20070718
PRIORITY APPLN. INFO.:			US 2002-394508P	P 20020709
			WO 2003-US22149	W 20030702
			US 2003-616365	A3 20030708

OTHER SOURCE(S): MARPAT 140:111429
GI



I

AB The title compds. (I) [Z1 = (CH2)q, CO; Z2 = (CH2)p, CO; D = CH, CO,

(CH2)m (where m = 0-3; p = 1, 2; q = 0-2); n = 0-2; Q = C, N; A = (CH2)x (where x = 1-5); A = (CH2)x1 (where x1 = 1-5) with an alkenyl bond or an alkynyl bond embedded anywhere in the chain; or A = -(CH2)x2-O-(CH2)x3- (where X2, X3 = 0 to 5, provided that at least one of x2 and x3 is other than 0); B = a bond or (CH2)x4 (where x4 = 1-5); X = CH, N; X2-X6 = C, N, O, or S and at least one of X2-X6 is C; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halogen, (un)substituted amino; R2a, R2b, R2c = H, alkyl, alkoxy, halogen, (un)substituted amino, cyano; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, etc.; E = CH, N; Z = (CH2)x5 (where x5 is 0, i.e. a single or a double bond, 1, 2), or Z is (CH2)x6 (where x6 = 2-5), where (CH2)x6 includes an alkenyl (C:C) bond embedded within the chain or Z = -(CH2)x7-O-(CH2)x8- (where x7, x8 = 0-4); (CH2)x to (CH2)x8, (CH2)m, (CH2)n, (CH2)p and (CH2)q may be optionally substituted; Y = CO2R4 (where R4 = H, alkyl, or a prodrug ester), or Y = a C-linked 1-tetrazole, a phosphinic acid of the structure P(O)(OR4a)R5 [where R4a = H, a prodrug ester; R5 = alkyl or aryl, or a phosphonic acid of the structure P(O)(OR4a)2]] including all stereoisomers, prodrug esters, and pharmaceutically acceptable salts thereof are prepared These compds., e.g. cis-1-ethoxycarbonyl-4-[3-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]phenyl]pyrrolidin-3-ylacetic acid and cis-1-(6-trifluoromethylpyrimidin-2-yl)-4-[3-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]phenyl]pyrrolidine-3-carboxylic acid, modulate serum levels of blood glucose, triglyceride, insulin, and nonesterified fatty acid (NEFA) levels, and thus are particularly useful in the treatment of diabetes and obesity, especially Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia,
hyperlipidemia, obesity, atherosclerosis, and related diseases employing such substituted acid derivs. alone or in combination with another antidiabetic agent and/or a hypolipidemic agent and/ or other therapeutic agents. Disclosed is a method for treating diabetes, especially Type 2 diabetes, and related diseases such as insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, inflammation, Syndrome X, diabetic complications, dysmetabolic syndrome, atherosclerosis, and related diseases, which comprises administering to a patient in need of treatment a therapeutically effective amount of the compound I. Also disclosed is a method for treating early malignant lesions (such as ductal carcinoma in situ of the breast and lobular carcinoma in situ of the breast), premalignant lesions including fibroadenoma of the breast and prostatic intraepithelial neoplasia (PIN), liposarcomas and various other epithelial tumors (including breast, prostate, colon, ovarian, gastric and lung), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and osteoporosis and proliferative diseases such as psoriasis, which comprises administering to a patient in need of treatment a therapeutically effective amount of the compound I.

IT 647001-96-5P 647001-97-6P 647001-98-7P
647001-99-8P 647002-00-4P 647002-01-5P
647002-02-6P 647002-03-7P 647002-04-8P
647002-05-9P 647002-06-0P 647002-07-1P
647002-08-2P 647002-09-3P 647002-10-6P
647002-11-7P 647002-12-8P 647002-13-9P
647002-14-0P 647002-15-1P 647002-16-2P
647002-17-3P 647002-18-4P 647002-19-5P
647002-20-8P 647002-21-9P 647002-22-0P
647002-23-1P 647002-24-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as antidiabetic and antiobesity agents)

RN 647001-96-5 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-(phenylmethyl)-, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647001-97-6 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-(phenylmethyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647001-98-7 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-[4-(trifluoromethyl)-2-pyrimidinyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647001-99-8 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-phenyl ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-00-4 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-ethyl ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-01-5 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-ethyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647002-02-6 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-ethyl ester, (3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647002-03-7 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-phenyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647002-04-8 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-phenyl ester, (3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647002-05-9 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-propyl ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-06-0 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(1-methylethyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-07-1 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-butyl ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-08-2 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(2-methylpropyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-09-3 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(2,2-dimethylpropyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-10-6 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(phenylmethyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-11-7 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-fluorophenyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-12-8 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-chlorophenyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-13-9 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-bromophenyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-14-0 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-methylphenyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-15-1 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-methoxyphenyl) ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-16-2 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(1-methylethyl) ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-17-3 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-butyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-18-4 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(2-methylpropyl) ester, (3R,4R)-rel-
(CA INDEX NAME)

Relative stereochemistry.



RN 647002-19-5 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(2,2-dimethylpropyl) ester, (3R,4R)-rel-
(CA INDEX NAME)

Relative stereochemistry.



RN 647002-20-8 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-fluorophenyl) ester, (3R,4R)-rel-
(CA INDEX NAME)

Relative stereochemistry.



RN 647002-21-9 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-chlorophenyl) ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-22-0 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-bromophenyl) ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-23-1 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-methylphenyl) ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647002-24-2 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1-(4-methoxyphenyl) ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 647006-37-9P 647006-38-0P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as antidiabetic and antiobesity agents)
RN 647006-37-9 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester, (3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647006-38-0 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-[4-(trifluoromethyl)-2-pyrimidinyl]-, methyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 477774-28-0P 477774-29-1P 477774-36-0P
585569-20-6P 585569-21-7P 585569-22-8P
585569-23-9P 585569-24-0P 647003-76-7P
647003-85-8P 647003-86-9P 647003-95-0P
647003-96-1P 647004-04-4P 647006-33-5P
647006-34-6P 647006-35-7P 647006-36-8P
647006-39-1P 647006-40-4P 647006-41-5P
647832-89-1P 647832-90-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as antidiabetic and antiobesity agents)

RN 477774-28-0 CAPLUS
CN Benzeneethanol, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477774-29-1 CAPLUS
CN Benzeneacetaldehyde, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477774-36-0 CAPLUS
CN 2-Butenoic acid, 4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, 1,1-dimethylethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 585569-20-6 CAPLUS
CN Benzenepropanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 585569-21-7 CAPLUS
CN Benzenepropanol, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 585569-22-8 CAPLUS
CN Benzenepropanal, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 585569-23-9 CAPLUS
CN 2-Pentenoic acid, 5-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, methyl ester, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 585569-24-0 CAPLUS
CN 2-Pentenoic acid, 5-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 647003-76-7 CAPLUS
CN 2-Butenoic acid, 4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, methyl ester, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 647003-85-8 CAPLUS
CN 2-Butynoic acid, 4-hydroxy-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 647003-86-9 CAPLUS
CN 2-Butynoic acid, 4-(acetyloxy)-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 647003-95-0 CAPLUS
CN 3H-3a,6-Methano-2,1-benzisothiazole, hexahydro-8,8-dimethyl-1-[(2Z)-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-1-oxo-2-butenyl]-, 2,2-dioxide, (3aS,6R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 647003-96-1 CAPLUS
CN 3H-3a,6-Methano-2,1-benzisothiazole, hexahydro-8,8-dimethyl-1-[(2E)-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-1-oxo-2-butenyl]-, 2,2-dioxide, (3aS,6R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 647004-04-4 CAPLUS
CN 2-Butynoic acid, 4-(acetyloxy)-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, ethyl ester (CA INDEX NAME)



RN 647006-33-5 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-(phenylmethyl)-, methyl ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647006-34-6 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-(phenylmethyl)-, methyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647006-35-7 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647006-36-8 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647006-39-1 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 3-methyl 1-phenyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 647006-40-4 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647006-41-5 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 3-methyl 1-(1-methylethyl) ester, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 647832-89-1 CAPLUS
CN 3H-3a,6-Methano-2,1-benzisothiazole, hexahydro-8,8-dimethyl-1-[(2Z)-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-1-oxo-2-butenyl]-, 2,2-dioxide, (3aR,6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 647832-90-4 CAPLUS
CN 3H-3a,6-Methano-2,1-benzisothiazole, hexahydro-8,8-dimethyl-1-[(2E)-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-1-oxo-2-butenyl]-, 2,2-dioxide, (3aR,6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:696736 CAPLUS
DOCUMENT NUMBER: 139:230769
TITLE: Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus and atherosclerosis
INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072102	A1	20030904	WO 2003-US2680	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003214932	A1	20030909	AU 2003-214932	20030213
EP 1480642	A1	20041201	EP 2003-710780	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005528346	T	20050922	JP 2003-570848	20030213
US 2006084663	A1	20060420	US 2004-505103	20040817
US 7259175	B2	20070821		

PRIORITY APPLN. INFO.: US 2002-359807P P 20020225
WO 2003-US2680 W 20030213

OTHER SOURCE(S): MARPAT 139:230769
GI



I



II

AB Title compds. I [wherein R3 = H or alkoxy; R4 = H or alkyl; R5 = alkyl, alkenyl, or (un)substituted aryl(oxy)alkyl or arylthioalkyl; R6 = CF3, OCF3, (hydroxy)alkyl, alkylcarbamoyl, carboxyalkoxy, or (un)substituted aryloxy, arylthio, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 and R10 = independently H, alkyl, alkenyl, or alkoxy; T1 = C or N; Q = bond, O, O(CH2)q, or C; q = 1-2; W = O, S, SO2, NHSO2, etc.; X = CmH2m; m = 0-2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or (un)substituted alkyl or arylmethyl; and pharmaceutically acceptable salts thereof] were prepared as peroxisome proliferator activated receptor (PPAR) agonists (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was coupled with 5-chloromethyl-4-phenethyl-2-(4-trifluoromethylphenyl)thiazole in the presence of Cs2CO3 in MeCN to give the (phenylthiomethyl)thiazole (83.5%), which was saponified with LiOH in THF to provide II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus and atherosclerosis (no data).

IT 592518-79-1P, [3-[2-[5-Ethyl-2-(4-trifluoromethylphenyl)thiazol-4-yl]ethoxy]phenyl]acetic acid 592518-87-1P, [3-[2-[5-Propyl-2-(4-trifluoromethylphenyl)thiazol-4-yl]ethoxy]phenyl]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR agonist; preparation of PPAR agonists for treating diabetes mellitus and atherosclerosis)

RN 592518-79-1 CAPLUS

CN Benzeneacetic acid, 3-[2-[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 592518-87-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-propyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)



IT 592518-82-6P, [3-[2-[5-Ethyl-2-(4-trifluoromethylphenyl)thiazol-4-yl]ethoxy]phenyl]acetic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of PPAR agonists for treating diabetes mellitus and atherosclerosis)
RN 592518-82-6 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:696734 CAPLUS
DOCUMENT NUMBER: 139:230768
TITLE: Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease
INVENTOR(S): Conner, Scott Eugene; Knobelsdorf, James Allen; Mantlo, Nathan Bryan; Schkeryantz, Jeffrey Michael; Shen, Quanrong; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072100	A1	20030904	WO 2003-US2679	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003217274	A1	20030909	AU 2003-217274	20030213
EP 1480640	A1	20041201	EP 2003-713316	20030213
EP 1480640	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005529077	T	20050929	JP 2003-570846	20030213
AT 369855	T	20070915	AT 2003-713316	20030213
ES 2290439	T3	20080216	ES 2003-713316	20030213
US 2005107449	A1	20050519	US 2004-505089	20040817
US 7153878	B2	20061226		

PRIORITY APPLN. INFO.: US 2002-359808P P 20020225
WO 2003-US2679 W 20030213

OTHER SOURCE(S): MARPAT 139:230768
GI



I



II

AB Title compds. I [wherein R3, R4, R30, and R40= independently H, alkyl, halo, or alkoxy; R5 = (un)substituted alkyl, alkenyl, aryl(oxy)alkyl, or arylthioalkyl; or when R5 = alkyl, R5 may be combined with W to form a heterocycloalkyl fused to the oxazole or thiazole ring; R6 = trihalomethyl, trihalomethoxy, (hydroxy)alkyl, alkylcarbamoyl, tetramethyldioxaborolanyl, halo, alkanoyl, carboxyalkoxy, (cyclo)alkoxy, tetrahydropyranyloxy, morpholinyl, or (un)substituted aryloxy, arylthio, heterocycliyloxy, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 = (un)substituted (aryl)alkyl or alkenyl; R10 = H or alkyl; Q = a bond, O, or CH2; T1 = C or N; W = CH2, O, OCH2, S, SO2, or (un)substituted CONH, NH, or NHCH2; X = C, CH2C, or CCH2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as peroxisome proliferator activated receptor δ (PPARδ) modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was condensed with 1-[4-[2-(2-chloro-6-fluorophenyl)ethyl]-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethanol in the presence of PBu3 and 1,1'-(azodicarbonyl)bipiperidine in toluene. Deesterification with LiOH in THF produced II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus, syndrome X, and cardiovascular disease (no data).

IT 591776-04-4P, (R)-[3-[2-[5-Methyl-2-(4-trifluoromethylphenyl)thiazol-4-yl]propoxy]phenyl]acetic acid 591776-21-5P, (S)-[3-[2-[5-Methyl-2-(4-trifluoromethylphenyl)thiazol-4-yl]propoxy]phenyl]acetic acid 591776-25-9P, [3-[2-[5-Ethyl-2-(4-trifluoromethylphenyl)thiazol-4-yl]propoxy]phenyl]acetic acid 591776-84-0P, [3-[2-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]propoxy]phenyl]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; preparation of PPAR modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease)

RN 591776-04-4 CAPLUS

CN Benzeneacetic acid, 3-[(2R)-2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]propoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 591776-21-5 CAPLUS
CN Benzeneacetic acid, 3-[(2S)-2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]propoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 591776-25-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]propoxy]- (CA INDEX NAME)



RN 591776-84-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:656421 CAPLUS
DOCUMENT NUMBER: 139:197489
TITLE: Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 153,454.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003158232	A1	20030821	US 2002-294525	20021114
US 6967212	B2	20051122		
US 2003092736	A1	20030515	US 2002-153454	20020522
US 2005124661	A1	20050609	US 2004-12810	20041215
PRIORITY APPLN. INFO.:			US 2001-294380P	P 20010530
			US 2002-153454	A2 20020522
			US 2002-294525	A3 20021114

OTHER SOURCE(S): MARPAT 139:197489
GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; ≥1 of x2, x3 ≠ 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor-γ (PPARγ) and stimulators of peroxisome proliferator activated receptor-α (PPARα). Thus, title compound

(II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPARα and to PPARγ ligand binding domains with IC50 = 69 nM.

IT 477773-78-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; prepn of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 477773-78-7 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxylic acid, 5-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-2-phenyl- (CA INDEX NAME)



IT 244149-78-8P 244151-17-5P 477773-87-8P
477773-88-9P 477773-89-0P 477773-90-3P
477774-09-7P 477774-28-0P 477774-29-1P
477774-30-4P 477774-36-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 244149-78-8 CAPLUS

CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244151-17-5 CAPLUS

CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477773-87-8 CAPLUS

CN Benzeneacetyl chloride, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477773-88-9 CAPLUS
CN 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 477773-89-0 CAPLUS
CN Benzenebutanamide, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (CA INDEX NAME)



RN 477773-90-3 CAPLUS
CN Benzenebutanamide, α-diazo-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (CA INDEX NAME)



RN 477774-09-7 CAPLUS
CN 2-Butynoic acid, 4-hydroxy-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, ethyl ester (CA INDEX NAME)



RN 477774-28-0 CAPLUS

CN Benzeneethanol, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477774-29-1 CAPLUS
CN Benzeneacetaldehyde, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477774-30-4 CAPLUS
CN 2-Butenoic acid, 4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 477774-36-0 CAPLUS
CN 2-Butenoic acid, 4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, 1,1-dimethylethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT 585569-11-5P 585569-19-3P 585569-27-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents)
RN 585569-11-5 CAPLUS
CN 2H-1,2,3-Triazole-4-carboxylic acid, 5-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-2-phenyl- (CA INDEX NAME)



RN 585569-19-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-phenyl- (CA INDEX NAME)



RN 585569-27-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-phenyl- (CA INDEX NAME)



IT 585569-18-2P 585569-20-6P 585569-21-7P
585569-22-8P 585569-23-9P 585569-24-0P
585569-25-1P 585569-26-2P 585569-36-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 585569-18-2 CAPLUS
CN 2H-1,2,3-Triazole-4-carboxamide, 5-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N,2-diphenyl- (CA INDEX NAME)



RN 585569-20-6 CAPLUS
CN Benzenepropanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 585569-21-7 CAPLUS
CN Benzenepropanol, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 585569-22-8 CAPLUS
CN Benzenepropanal, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 585569-23-9 CAPLUS
CN 2-Pentenoic acid, 5-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, methyl ester, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 585569-24-0 CAPLUS
CN 2-Pentenoic acid, 5-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 585569-25-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (CA INDEX NAME)



RN 585569-26-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-phenyl-, methyl ester (CA INDEX NAME)



RN 585569-36-4 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 4-[2-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-1-phenyl-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964190 CAPLUS
DOCUMENT NUMBER: 138:39272
TITLE: Preparation of 3-(oxazolylalkoxyphenyl)propionic acids and analogs as modulators of peroxisome proliferator activated receptors for treatment of diabetes and related conditions
INVENTOR(S): Gossett, Lynn Stacy; Green, Jonathan Edward; Henry, James Robert; Jones, Winton Dennis, Jr.; Matthews, Donald Paul; Shen, Quan Rong; Smith, Daryl Lynn; Vance, Jennifer Ann; Warshawsky, Alan M.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100403	A1	20021219	WO 2002-US15143	20020524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448552	A1	20021219	CA 2002-2448552	20020524
AU 2002316105	A1	20021223	AU 2002-316105	20020524
NZ 529550	A	20031219	NZ 2002-529550	20020524
EP 1401434	A1	20040331	EP 2002-746380	20020524
EP 1401434	B1	20061115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010167	A	20040406	BR 2002-10167	20020524
HU 2004000268	A2	20040728	HU 2004-268	20020524
JP 2005502600	T	20050127	JP 2003-503224	20020524
CN 1578659	A	20050209	CN 2002-815453	20020524
AT 345128	T	20061215	AT 2002-746380	20020524
ES 2275887	T3	20070616	ES 2002-746380	20020524
US 2005075378	A1	20050407	US 2003-477405	20031112
US 7282501	B2	20071016		
ZA 2003009059	A	20050810	ZA 2003-9059	20031120
MX 2003PA10903	A	20040217	MX 2003-PA10903	20031127
IN 2003KN01573	A	20060317	IN 2003-KN1573	20031203
PRIORITY APPLN. INFO.:			US 2001-296701P P	20010607
			WO 2002-US15143 W	20020524

OTHER SOURCE(S): MARPAT 138:39272
GI



I



II

AB Title compds. I [wherein n = 2-5; V = a bond or O; X = CH2 or O; p = 0 or 1; m = 1-4; Y1 = (un)substituted (hetero)aryl; Y2 and Y3 = independently H, alkyl, or alkoxy; Y4 = (un)substituted alk(en/yn)ylaminoalkyl, carboxyaminoalkyl, (thio)ureidoalkyl, carbamoylalkyl, aminoalkyl, alkoxyalkyl, alkylthioalkyl, or CN; R5 = H or alkyl; and pharmaceutically acceptable salts, solvates, hydrates, or stereoisomers thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, 3-[2-(1,3-dioxo-1,3-dihydroisoindolo-2-ylmethyl)-4-hydroxyphenyl]propionic acid tert-Bu ester was coupled with toluene-4-sulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester in the presence of Cs2CO3 in DMF. Deprotection of the amine using NaBH4 in isopropanol followed by conversion to the carbamate and deesterification gave II. I are useful for the treatment of Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X, as well as cardiovascular diseases (no data).

IT 478541-73-0P, 3-[2-(2-Isopropoxycarbonylethyl)-4-[2-[5-methyl-2-(6-phenoxypyridin-3-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478543-87-2P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478543-95-2P, 3-[2-[2-(Butylsulfonylamino)ethyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478543-96-3P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[2-[(2-pyridylcarbonyl)amino]ethyl]phenyl]propionic acid 478543-97-4P, 3-[2-[2-[(2,5-Dichloro-3-thienylcarbonyl)amino]ethyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478543-98-5P 478543-99-6P, 3-[2-[2-(Cyclobutylcarbonylamino)ethyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-00-2P, 3-[2-(2-Benzoylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-01-3P, 3-[2-(2-Isobutoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-02-4P, 3-[2-(2-Benzyloxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-03-5P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-[4-(morpholin-4-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478544-05-7P,

3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-[2-(isopropoxycarbonylamino)ethyl]phenyl]propionic acid 478544-06-8P, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-(2-isopropoxycarbonylaminoethyl)phenyl]propionic acid 478544-07-9P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478544-08-0P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-(pyridin-2-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478544-10-4P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-(4-phenylaminophenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478544-11-5P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-[4-(methylphenylamino)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; preparation of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

RN 478541-73-0 CAPLUS
CN 1,2-Benzenedipropanoic acid, 4-[2-[5-methyl-2-(6-phenoxy-3-pyridinyl)-4-oxazolyl]ethoxy]-, α2-(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 478543-87-2 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 478543-95-2 CAPLUS
CN Benzenepropanoic acid, 2-[2-[(butylsulfonyl)amino]ethyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 478543-96-3 CAPLUS
CN Benzenepropanoic acid, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-[2-[(2-pyridinylcarbonyl)amino]ethyl]- (CA INDEX NAME)



RN 478543-97-4 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(2,5-dichloro-3-thienyl)carbonyl]amino]ethyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 478543-98-5 CAPLUS
CN Benzenepropanoic acid, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-[2-[(phenylacetyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 478543-99-6 CAPLUS
CN Benzenepropanoic acid, 2-[2-[(cyclobutylcarbonyl)amino]ethyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 478544-00-2 CAPLUS
CN Benzenepropanoic acid, 2-[2-(benzoylamino)ethyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 478544-01-3 CAPLUS
CN Benzenepropanoic acid, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-[2-[[(2-methylpropoxy)carbonyl]amino]ethyl]- (CA INDEX NAME)



RN 478544-02-4 CAPLUS
CN Benzenepropanoic acid, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]- (CA INDEX NAME)



RN 478544-03-5 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]-4-[2-

[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 478544-05-7 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-[1,1'-biphenyl]-3-yl-5-methyl-4-oxazolyl)ethoxy]-2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]- (CA INDEX NAME)



RN 478544-06-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]- (CA INDEX NAME)



RN 478544-07-9 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]-4-[2-[5-methyl-2-(4-morpholinyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 478544-08-0 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]-4-[2-[5-methyl-2-(2-pyridinyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)



RN 478544-10-4 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]-4-[2-[5-methyl-2-[4-(phenylamino)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 478544-11-5 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]-4-[2-[5-methyl-2-[4-(methylphenylamino)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



IT 478543-92-9P, 3-[2-(2-tert-Butoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid methyl ester 478543-93-0P, 3-[2-(2-Aminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid methyl ester 478543-94-1P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

RN 478543-92-9 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 478543-93-0 CAPLUS
CN Benzenepropanoic acid, 2-(2-aminoethyl)-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 478543-94-1 CAPLUS
CN Benzenepropanoic acid, 2-[2-[[(1-methylethoxy)carbonyl]amino]ethyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:927185 CAPLUS
DOCUMENT NUMBER: 138:24716
TITLE: Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096358	A2	20021205	WO 2002-US16633	20020523
WO 2002096358	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449160	A1	20021205	CA 2002-2449160	20020523
AU 2002259306	A1	20021209	AU 2002-259306	20020523
AU 2002259306	B2	20070208		
EP 1390363	A2	20040225	EP 2002-729306	20020523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200400650	T3	20040621	TR 2004-650	20020523
HU 2004001504	A2	20041129	HU 2004-1504	20020523
JP 2004536070	T	20041202	JP 2002-592871	20020523
TW 235061	B	20050701	TW 2002-91111100	20020524
MX 2003PA10997	A	20040227	MX 2003-PA10997	20031128

PRIORITY APPLN. INFO.: US 2001-294380P P 20010530
WO 2002-US16633 W 20020523

OTHER SOURCE(S): MARPAT 138:24716
GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; ≥1 of x2, x3 ≠ 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, alkyl(halo)aryloxycarbonyl, alkoxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkyl, aminocarbonyl, substituted aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aryloxyarylalkyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylsulfinylarylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor-γ (PPARγ) and stimulators of peroxisome proliferator activated receptor-α (PPARα). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPARα and to PPARγ ligand binding domains with IC50 = 69 nM.

IT 477773-78-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; prepn of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 477773-78-7 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxylic acid, 5-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-2-phenyl- (CA INDEX NAME)



IT 244149-78-8P 244151-17-5P 477773-87-8P
477773-88-9P 477773-89-0P 477773-90-3P
477774-09-7P 477774-28-0P 477774-29-1P
477774-30-4P 477774-36-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 244149-78-8 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244151-17-5 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477773-87-8 CAPLUS
CN Benzeneacetyl chloride, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477773-88-9 CAPLUS
CN 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 477773-89-0 CAPLUS
CN Benzenebutanamide, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (CA INDEX NAME)



RN 477773-90-3 CAPLUS
CN Benzenebutanamide, α-diazo-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (CA INDEX NAME)



RN 477774-09-7 CAPLUS
CN 2-Butynoic acid, 4-hydroxy-4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, ethyl ester (CA INDEX NAME)



RN 477774-28-0 CAPLUS
CN Benzeneethanol, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477774-29-1 CAPLUS

CN Benzeneacetaldehyde, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 477774-30-4 CAPLUS
CN 2-Butenoic acid, 4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 477774-36-0 CAPLUS
CN 2-Butenoic acid, 4-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-, 1,1-dimethylethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:637483 CAPLUS
DOCUMENT NUMBER: 137:185311
TITLE: Preparation of 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
INVENTOR(S): Adams, Alan D.; Jones, A. Brian; Berger, Joel P.; Dropinski, James F.; Elbrecht, Alexander; Liu, Kun; Macnaul, Karen Lamb; Shi, Guo-qiang; Von, Langen Derek J.; Zhou, Gaochao
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064094	A2	20020822	WO 2002-US4680	20020205
WO 2002064094	A3	20030612		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437118	A1	20020822	CA 2002-2437118	20020205
AU 2002251978	A1	20020828	AU 2002-251978	20020205
AU 2002251978	B2	20070719		
EP 1366012	A2	20031203	EP 2002-721022	20020205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521124	T	20040715	JP 2002-563891	20020205
US 2004092596	A1	20040513	US 2003-470954	20030730
US 7091230	B2	20060815		
US 2006122242	A1	20060608	US 2006-334152	20060118

PRIORITY APPLN. INFO.:
US 2001-267809P P 20010209
WO 2002-US4680 W 20020205
US 2003-470954 A3 20030730

OTHER SOURCE(S): MARPAT 137:185311
GI



I



II

AB Title compds. I [R1 = halo, alkyl, alkoxy; R2 = alkyl, alicyclic; R3 = alkyl, aryl, alicyclic, heterocycle, etc.; R4 = H, OH, alkoxy, aryloxy, halo or R3-4 may be joined together to yield 5- or 6-membered heterocycle; R5 = H, halo; R6 = H, halo, CH3, CF3; Ar1 = Ph, thienyl, thiazolyl, oxazolyl, pyridyl; X = O, S; Z = COOH, tetrazole, carboxamide] were prepared For instance, 2,4-dipropylresorcinol was converted to 2,4-dihydroxy-3,5-dipropyl-α,α,α-trifluoroacetophenone (CH2Cl2, TFAA, AlCl3) and subsequently treated with i. hydroxylamine•HCl, MeOH, reflux; ii. Ac2O; iii. pyridine, reflux which afforded 5,7-dipropyl-6-hydroxy-3-trifluoromethyl-1,2-benzisoxazole. The benzisoxazole was reacted with Me 2-bromo-2-phenylacetate (DMF, Cs2CO3) and the product saponified to give II. I are potent agonists of the peroxisome proliferator activated receptor and are useful in the treatment of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR-α and/or PPAR-γ mediated diseases.

IT 449779-48-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders)

RN 449779-48-0 CAPLUS

CN Benzeneacetic acid, 4-chloro-α-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2,6-dipropylphenoxy]- (CA INDEX NAME)



IT 449780-20-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders)

RN 449780-20-5 CAPLUS

CN Benzeneacetic acid, 4-chloro-α-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2,6-dipropylphenoxy]-, methyl ester (CA INDEX NAME)



L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:502825 CAPLUS
DOCUMENT NUMBER: 137:63237
TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T.; Devasthale, Pratik; Jeon, Yoon; Chen, Sean; Zhang, Hao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 190 pp., Cont.-in-part of U.S. Ser. No. 664,598. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6414002	B1	20020702	US 2001-812960	20010320
EP 1589006	A1	20051026	EP 2005-10760	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2003069275	A1	20030410	US 2002-80965	20020222
US 6919358	B2	20050719		
US 2003087935	A1	20030508	US 2002-81075	20020222
US 6727271	B2	20040427		
US 2003096846	A1	20030522	US 2002-80981	20020222
US 6653314	B2	20031125		
US 2004171644	A1	20040902	US 2003-655876	20030905
US 7084162	B2	20060801		
US 2004147560	A1	20040729	US 2003-737210	20031216
US 7053106	B2	20060530		
US 2005119311	A1	20050602	US 2004-964395	20041013
US 7241780	B2	20070710		
US 2007015797	A1	20070118	US 2005-155965	20050822

PRIORITY APPLN. INFO.:	US 1999-155400P	P	19990922
	US 2000-664598	A2	20000918
	EP 2000-965172	A3	20000919
	US 2001-812960	A3	20010320
	US 2002-80965	A3	20020222
	US 2002-80981	A3	20020222
	US 2002-81075	A3	20020222
	US 2003-655876	A3	20030905

OTHER SOURCE(S): MARPAT 137:63237
GI



I



II

AB Title compds. I [wherein Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2] were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). For example, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0°-room temperature to give 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde (65%). Addition of N-benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane afforded the benzylamine derivative (55%), which was stirred with aqueous NaOH in MeOH for 14 h to give the title compound II (71%). I are useful for the treatment of diabetes, especially Type II diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases (no data).

IT 331744-63-9P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-77-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331744-63-9 CAPLUS

CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)



RN 331744-77-5 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)



IT 174258-60-7P, Ethanone, 1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- 331746-06-6P, Glycine, N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-07-7P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 174258-60-7 CAPLUS
CN Ethanone, 1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 331746-06-6 CAPLUS
CN Glycine, N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (CA INDEX NAME)



RN 331746-07-7 CAPLUS
CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:171871 CAPLUS
DOCUMENT NUMBER: 136:232294
TITLE: Oxazolyl-aryloxyacetic acid derivatives and thiazole analogs and their use as PPAR agonists, e.g., as antidiabetics and hypolipidemics
INVENTOR(S): Brooks, Dawn Alisa; Connor, Scott Eugene; Dominianni, Samuel James; Godfrey, Alexander Glenn; Gossett, Lann Stacy; Rito, Christopher John; Tripp, Allie Edward; Warshawsky, Alan M.; Winneroski, Leonard Larry; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018355	A1	20020307	WO 2001-US22615	20010823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420178	A1	20020307	CA 2001-2420178	20010823
AU 2001084658	A	20020313	AU 2001-84658	20010823
EP 1313715	A1	20030528	EP 2001-963732	20010823
EP 1313715	B1	20070801		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509084	T	20040325	JP 2002-523473	20010823
AT 368653	T	20070815	AT 2001-963732	20010823
ES 2288982	T3	20080201	ES 2001-963732	20010823
US 2004024034	A1	20040205	US 2003-343474	20030129
US 6982278	B2	20060103		
US 2005250825	A1	20051110	US 2005-181640	20050714

PRIORITY APPLN. INFO.: US 2000-227233P P 20000823
WO 2001-US22615 W 20010823
US 2003-343474 A3 20030129

OTHER SOURCE(S): MARPAT 136:232294
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title oxazoles I and their pharmaceutically acceptable salts, solvates, and hydrates are disclosed [wherein R1 = (un)substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl, or cycloalkyl-alkyl; R2 = H, alkyl, or haloalkyl; n = 2, 3, or 4, with the resultant polymethylene chain optionally containing a carbon-carbon double bond; W = O or S; Y = (un)substituted phenylene, naphthylene, or 1,2,3,4-tetrahydronaphthylene; R3 = H, alkyl, or haloalkyl; R4 = H, alkyl, haloalkyl or (un)substituted PhCH2; provided that when R3 = R4 = H, then

R2 = alkyl or haloalkyl; R5 = H, alkyl, aminoalkyl]. Approx. 120 examples are given. One example of a thiazole analog is also given. The compds. are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus. For instance, 2-(3-bromophenyl)-4-(chloromethyl)-5-methyloxazole (prepared in 2 steps) underwent cyanation, hydrolysis to an acid, reduction to an alc., tosylation, and etherification with the corresponding phenol derivative to give intermediate bromide II. The latter compound underwent Pd-catalyzed ethynylation, hydrogenation of the ethynyl group, and alkaline hydrolysis, to give title compound III. This compound bound to human PPARα and PPARγ receptors in vitro with IC50 values of 31 and 219 nM, resp., vs. values of 94,500 and 1180 for troglitazole, and 68,000 and 125,000 for fenofibric acid. At 30 mg/kg orally in mice (transgenic for human apoAI), III gave a 74.3% reduction in serum triglycerides and a 180% increase in high-d. lipoprotein cholesterol, vs. 41% and 48% for fenofibrate. III also gave complete normalization of blood glucose in diabetic mice at 30 mg/kg orally.

IT 403610-41-3P, [4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-propylphenoxy]acetic acid 403610-43-5P, [4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2,6-dipropylphenoxy]acetic acid 403610-45-7P, [2-Ethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid 403610-54-8P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-pentylphenoxy]propionic acid 403611-18-7P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-propylphenoxy]propionic acid 403611-21-2P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2,6-dipropylphenoxy]propionic acid 403611-25-6P, 2-[2-Ethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403611-27-8P, [2-Isobutyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid 403611-29-0P, 2-[2-Isobutyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403611-31-4P, [4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(5-phenylpentyl)phenoxy]acetic acid 403611-32-5P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-(5-phenylpentyl)phenoxy]propionic acid 403611-34-7P, [2-Butyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid 403611-36-9P, 2-[2-Butyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403611-42-7P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-phenethylphenoxy]propionic acid 403611-43-8P, 2-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-phenethylphenoxy]-2-methylpropionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxazolyl-aryloxyacetic acid derivs. and thiazole analogs and their use as PPAR agonists)

RN 403610-41-3 CAPLUS

CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-propylphenoxy]- (9CI) (CA INDEX NAME)

RN 403610-43-5 CAPLUS
CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2,6-dipropylphenoxy]- (9CI) (CA INDEX NAME)



RN 403610-45-7 CAPLUS
CN Acetic acid, [2-ethyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 403610-54-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pentylphenoxy]- (CA INDEX NAME)



RN 403611-18-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-propylphenoxy]- (CA INDEX NAME)



RN 403611-21-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2,6-dipropylphenoxy]- (CA INDEX NAME)



RN 403611-25-6 CAPLUS
CN Propanoic acid, 2-[2-ethyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]-2-methyl- (CA INDEX NAME)



RN 403611-27-8 CAPLUS
CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(2-methylpropyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 403611-29-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(2-methylpropyl)phenoxy]- (CA INDEX NAME)



RN 403611-31-4 CAPLUS
CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(5-phenylpentyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 403611-32-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(5-phenylpentyl)phenoxy]- (CA INDEX NAME)



RN 403611-34-7 CAPLUS
CN Acetic acid, [2-butyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]-(9CI) (CA INDEX NAME)



RN 403611-36-9 CAPLUS
CN Propanoic acid, 2-[2-butyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]-2-methyl- (CA INDEX NAME)



RN 403611-42-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]- (CA INDEX NAME)



RN 403611-43-8 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl- (CA INDEX NAME)



IT 328919-42-2P, 2-[4-[2-[2-(Biphenyl-4-yl)-5-methyloxazol-4-yl]ethoxy]-2-phenethylphenoxy]-2-methylpropionic acid ethyl ester
328919-43-3P, 2-[4-[2-[2-(Biphenyl-3-yl)-5-methyloxazol-4-yl]ethoxy]-2-phenethylphenoxy]-2-methylpropionic acid ethyl ester
403612-19-1P, [4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-propylphenoxy]acetic acid ethyl ester 403612-20-4P,
2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-propylphenoxy]propionic acid ethyl ester 403612-28-2P,
[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2,6-dipropylphenoxy]acetic acid ethyl ester 403612-29-3P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2,6-dipropylphenoxy]propionic acid ethyl ester 403612-38-4P, [2-Ethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid ethyl ester 403612-39-5P,
2-[2-Ethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid ethyl ester 403612-40-8P,
[2-Isobutyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid ethyl ester 403612-41-9P, 2-[2-Isobutyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid ethyl ester 403612-42-0P, [4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(5-phenylpentyl)phenoxy]acetic acid ethyl ester 403612-43-1P,
2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-(5-phenylpentyl)phenoxy]propionic acid ethyl ester 403612-44-2P,
[2-Butyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid ethyl ester 403612-45-3P, 2-[2-Butyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid ethyl ester 403612-49-7P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-phenethylphenoxy]propionic acid ethyl ester
403612-50-0P, 2-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-phenethylphenoxy]-2-methylpropionic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of oxazolyl-aryloxyacetic acid derivs. and thiazole analogs and their use as PPAR agonists)

RN 328919-42-2 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl-, ethyl ester (CA

INDEX NAME)



RN 328919-43-3 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-3-yl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 403612-19-1 CAPLUS
CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-propylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403612-20-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-propylphenoxy]-, ethyl ester (CA INDEX NAME)



RN 403612-28-2 CAPLUS
CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2,6-dipropylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403612-29-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2,6-dipropylphenoxy]-, ethyl ester (CA INDEX NAME)



RN 403612-38-4 CAPLUS
CN Acetic acid, [2-ethyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403612-39-5 CAPLUS
CN Propanoic acid, 2-[2-ethyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 403612-40-8 CAPLUS
CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(2-methylpropyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403612-41-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(2-methylpropyl)phenoxy]-, ethyl ester (CA INDEX NAME)



RN 403612-42-0 CAPLUS
CN Acetic acid, [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(5-phenylpentyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403612-43-1 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(5-phenylpentyl)phenoxy]-, ethyl ester (CA INDEX NAME)



RN 403612-44-2 CAPLUS
CN Acetic acid, [2-butyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 403612-45-3 CAPLUS
CN Propanoic acid, 2-[2-butyl-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 403612-49-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)



RN 403612-50-0 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:704703 CAPLUS
DOCUMENT NUMBER: 135:257231
TITLE: Preparation of catechol propionic acid derivatives as peroxisome proliferator-activated receptor (PPAR) α and γ agonists
INVENTOR(S): Kadota, Hidetoshi; Fukazawa, Nobuyuki; Maruyama, Kyoko; Nakao, Toshifumi; Asada, Noriaki; Takebayashi, Nozomi; Kibayashi, Kenji; Uda, Hideyuki; Morikawa, Maki
PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001261612	A	20010926	JP 2000-79220	20000322
PRIORITY APPLN. INFO.:			JP 2000-79220	20000322

OTHER SOURCE(S): MARPAT 135:257231
GI



I



II

AB The title compds. I [R1 = alkyl, etc.; R2 = H, alkoxy, etc.; R3 = H, alkyl, etc.; R4 = H, alkyl, etc.; X = (un)substituted Ph, etc.] are prepared The PPAR α and γ agonist activities of the title compound II were demonstrated; II at 100 mg/kg gave 16% blood sugar decrease in STZ mice.

IT 362012-77-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of catechol propionic acid derivs. as peroxisome proliferator-activated receptor α and γ agonists)

RN 362012-77-9 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-methoxy-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



IT 362013-02-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of catechol propionic acid derivs. as peroxisome proliferator-activated receptor α and γ agonists)
RN 362013-02-3 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-methoxy-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:228872 CAPLUS
DOCUMENT NUMBER: 134:266299
TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents.
INVENTOR(S): Cheng, Peter T. W.; Devasthale, Pratik; Jeon, Yoon T.; Chen, Sean; Zhang, Hao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021602	A1	20010329	WO 2000-US25710	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 260321	B	20060821	TW 2000-89119155	20000918
CA 2388452	A1	20010329	CA 2000-2388452	20000919
CA 2388452	C	20070403		
EP 1218361	A1	20020703	EP 2000-965172	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014189	A	20020820	BR 2000-14189	20000919
TR 200200732	T2	20021021	TR 2002-732	20000919
JP 2003509503	T	20030311	JP 2001-524981	20000919
HU 2002004416	A2	20030428	HU 2002-4416	20000919
HU 2002004416	A3	20060130		
NZ 516820	A	20041126	NZ 2000-516820	20000919
AU 782031	B2	20050630	AU 2000-75935	20000919
EP 1589006	A1	20051026	EP 2005-10760	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
RU 2279427	C2	20060710	RU 2002-108928	20000919
IN 2002DN00107	A	20070406	IN 2002-DN107	20020128
ZA 2002000937	A	20030502	ZA 2002-937	20020201
MX 2002PA01847	A	20021023	MX 2002-PA1847	20020221
NO 2002001408	A	20020514	NO 2002-1408	20020321
NO 322500	B1	20061016		
HK 1049337	A1	20070729	HK 2003-101528	20030228

PRIORITY APPLN. INFO.:
US 1999-155400P P 19990922
EP 2000-965172 A3 20000919
WO 2000-US25710 W 20000919

OTHER SOURCE(S): MARPAT 134:266299
GI



I



II

AB Title compds. [I; Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2], were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). Thus, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0°-room temperature to give 65% 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde. This was stirred 12 h with N-benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane to give 55% benzylamine derivative, which was stirred 14 h with aqueous NaOH in MeOH to give 71% title compound (II).

IT 331744-63-9P 331744-77-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331744-63-9 CAPLUS

CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)



RN 331744-77-5 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)



IT 174258-60-7P 331746-06-6P 331746-07-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 174258-60-7 CAPLUS
CN Ethanone, 1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 331746-06-6 CAPLUS
CN Glycine, N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (CA INDEX NAME)



RN 331746-07-7 CAPLUS
CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:167982 CAPLUS
DOCUMENT NUMBER: 134:207811
TITLE: Preparation of biaryloxa(thia)zole derivatives as PPAR modulators
INVENTOR(S): Brooks, Dawn A.; Rito, Christopher J.; Shuker, Anthony J.; Dominianni, Samuel J.; Warshawsky, Alan M.; Gossett, Lynn S.; Matthews, Donald P.; Hay, David A.; Ardecky, Robert J.; Michellys, Pierre-Yves; Tyhonas, John S.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Ligand Pharmaceuticals Incorporated
SOURCE: PCT Int. Appl., 232 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016120	A1	20010308	WO 2000-US23358	20000823
WO 2001016120	A9	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2382966	A1	20010308	CA 2000-2382966	20000823
EP 1206457	A1	20020522	EP 2000-959401	20000823
EP 1206457	B1	20031015		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6417212	B1	20020709	US 2000-644457	20000823
JP 2003508389	T	20030304	JP 2001-519687	20000823
AT 252091	T	20031115	AT 2000-959401	20000823
PT 1206457	T	20040331	PT 2000-959401	20000823
ES 2204684	T3	20040501	ES 2000-959401	20000823
US 2003045558	A1	20030306	US 2002-121373	20020411
US 6610696	B2	20030826		
US 2004019090	A1	20040129	US 2003-434425	20030507
US 6825222	B2	20041130		

PRIORITY APPLN. INFO.:	US 1999-151162P	P	19990827
	US 2000-644457	A3	20000823
	WO 2000-US23358	W	20000823
	US 2002-121373	A3	20020411

OTHER SOURCE(S): MARPAT 134:207811
GI



I



II

AB Title compds. (I) [wherein n = 2-4; V = O or S; W = O, S, or SO2; R1 = H, alkyl, Ph, or CF3; R2 = independently H, (cyclo)alkyl, cycloalkylalkyl, aryl(alkyl), or together with the Ph to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 = independently H, (cyclo)alkyl, cycloalkylalkyl, or aryl(alkyl); R4 = independently H, alkyl, aryl, or benzyl; R5 = independently H or (un)substituted (hetero)aryl, provided that at least one R5 = (un)substituted (hetero)aryl; and R6 = H or (amino)alkyl] were prepared as are modulators of peroxisome proliferator activated receptors (PPARs) and are useful in the treatment of type II diabetes and cardiovascular diseases. For example, a mixture of the toluene-4-sulfonic acid 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethyl ester and 2-(3-hydroxyphenoxy)-2-methylpropanoic acid Et ester was heated at 55°C in DMF for 18 h and the intermediate deesterified using NaOH in EtOH and THF to afford the title compound II. II bound to human PPARα and PPARγ with IC50 values of 97 nM and 532 nM, resp., and activated human PPARα and PPARγ with efficacies of 97% and 70%, resp. In assays evaluating triglyceride and cholesterol levels in mice transgenic for human apoAI, administration of II reduced triglyceride serum levels by 60.5% and increased HDLc serum levels by 204%. Glucose normalization of 95% was attained in male diabetic (db/db) mice dosed with II.

IT 328919-42-2P 328919-43-3P 328920-05-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of biaryl oxa(thia)zole PPAR modulators by coupling biaryloxazolylalkyl tosylates with alcs. or thiols)

RN 328919-42-2 CAPLUS

CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 328919-43-3 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-3-yl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 328920-05-4 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-propylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



IT 328918-27-0P 328918-52-1P 328918-53-2P
328918-79-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl oxa(thia)zole PPAR modulators by coupling biaryloxazolylalkyl tosylates with alcs. or thiols)
RN 328918-27-0 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-propylphenoxy]-2-methyl- (CA INDEX NAME)



RN 328918-52-1 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 328918-53-2 CAPLUS
CN Propanoic acid, 2-[4-[2-(2-[1,1'-biphenyl]-3-yl-5-methyl-4-oxazolyl)ethoxy]-2-(2-phenylethyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 328918-79-2 CAPLUS
CN Acetic acid, [4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-propylphenoxy]- (9CI) (CA INDEX NAME)



IT 328920-04-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of biaryl oxa(thia)zole PPAR modulators by coupling biaryloxazolylalkyl tosylates with alcs. or thiols)
RN 328920-04-3 CAPLUS
CN Phenol, 4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]-2-propyl-

(CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:94931 CAPLUS
DOCUMENT NUMBER: 132:265154
TITLE: New Azolidinediones as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties
AUTHOR(S): Malamas, Michael S.; Sredy, Janet; Gunawan, Iwan; Mihan, Brenda; Sawicki, Diane R.; Seestaller, Laura; Sullivan, Donald; Flam, Brenda R.
CORPORATE SOURCE: Wyeth-Ayerst Research Inc., Princeton, NJ, 08543-8000, USA
SOURCE: Journal of Medicinal Chemistry (2000), 43(5), 995-1010
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Insulin resistance in the liver and peripheral tissues together with a pancreatic cell defect are the common causes of type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be neg. regulators of the insulin receptor. Inhibition of PTPases may be an effective method in the treatment of type 2 diabetes. A series of azolidinediones has been prepared as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Several compds. were potent inhibitors against the recombinant rat and human PTP1B enzymes with submicromolar IC50 values. Elongated spacers between the azolidinedione moiety and the central aromatic portion of the mol. as well as hydrophobic groups at the vicinity of this aromatic region were very important to the inhibitory activity. Oxadiazolidinediones (E)- and (Z)-I [R = H, CH2CO2H] were the best h-PTP1B inhibitors with IC50 values in the range of 0.12-0.3 μM. Several compds. normalized plasma glucose and insulin levels in the ob/ob and db/db diabetic mouse models.
IT 174258-61-8P 174259-12-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of phenyloxazolylalkoxyphenylalkyloxazolidinediones as protein tyrosine phosphatase inhibitors)
RN 174258-61-8 CAPLUS
CN 1,2,4-Oxadiazolidine-3,5-dione, 2-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-12-2 CAPLUS
CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:595118 CAPLUS
DOCUMENT NUMBER: 131:243262
TITLE: Preparation of carboxylic acid derivatives as PPAR regulating agents
INVENTOR(S): Tajima, Hisao; Nakayama, Yoshisuke; Fukushima, Daikichi
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9946232	A1	19990916	WO 1999-JP1134	19990309
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9932759	A	19990927	AU 1999-32759	19990309
EP 1067109	A1	20010110	EP 1999-939188	19990309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6506757	B1	20030114	US 2000-623913	20000911
US 2003153579	A1	20030814	US 2002-251805	20020923
US 7037914	B2	20060502		
US 2005250824	A1	20051110	US 2005-178639	20050712
US 7211591	B2	20070501		

PRIORITY APPLN. INFO.:

JP 1998-58444	A	19980310
JP 1998-87560	A	19980331
WO 1999-JP1134	W	19990309
US 2000-623913	A3	20000911
US 2002-251805	A3	20020923

OTHER SOURCE(S): MARPAT 131:243262
GI



I



II

AB The title compds. I [A1 = alkylene, etc.; A2 = O, S; A3 = CH, N; n = 1 - 5; R1 = H, alkyl, etc.; R2 = H, halo, etc.; Cyc1 = phenylene, etc.; Cyc2 = heterocyclic ring, etc.; R3 = H, nitro, etc.; R4 = 2,4-thiazolidinedion-5-yl, etc.; provisos are given] are prepared Because of their effect of regulating PPAR (peroxisome proliferator-activated receptor), the compds. of the general formula I are useful as hypoglycemic agents, lipid-lowering agents, preventives and/or remedies for diseases associating metabolic errors (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, arteriosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., HDL cholesterol-elevating agents, LDL cholesterol and/or VLDL cholesterol-lowering agents and drugs for relieving risk factors of diabetes or syndrome X. Formulations containing a compound of this invention are given. Phenyloxazolylethoxyphenylmethylthioacetic derivative II showed PPAR α agonist activity ; the blood sugar in mice treated with II (at 38.9 mg/kg/day for 2 days) was 214±19 mg/dL, vs. 495±35 mg/dL in controls.

IT 244149-61-9P 244149-62-0P 244149-63-1P
244149-71-1P 244149-78-8P 244149-99-3P
244150-06-9P 244150-39-8P 244150-40-1P
244150-41-2P 244150-42-3P 244150-43-4P
244150-44-5P 244150-48-9P 244150-49-0P
244150-50-3P 244150-51-4P 244150-52-5P
244150-53-6P 244150-58-1P 244150-61-6P
244150-62-7P 244150-63-8P 244150-64-9P
244150-65-0P 244150-66-1P 244150-67-2P
244150-68-3P 244150-69-4P 244150-70-7P
244150-71-8P 244150-72-9P 244150-73-0P
244150-74-1P 244150-75-2P 244150-76-3P
244150-77-4P 244150-78-5P 244150-79-6P
244150-80-9P 244150-82-1P 244150-83-2P
244150-84-3P 244150-87-6P 244150-88-7P
244150-89-8P 244150-90-1P 244150-91-2P
244150-92-3P 244151-00-6P 244151-01-7P
244151-02-8P 244151-10-8P 244151-17-5P
244151-38-0P 244151-45-9P 244151-90-4P
244151-93-7P 244151-95-9P 244151-96-0P
244151-97-1P 244151-98-2P 244152-08-7P
244152-10-1P 244152-13-4P 244152-16-7P
244152-18-9P 244152-21-4P 244152-30-5P
244152-35-0P 244152-37-2P 244152-39-4P
244152-40-7P 244152-41-8P 244152-42-9P
244152-43-0P 244152-44-1P 244152-45-2P
244152-46-3P 244152-47-4P 244152-48-5P
244152-49-6P 244152-50-9P 244152-51-0P
244152-52-1P 244152-53-2P 244152-54-3P
244152-55-4P 244152-56-5P 244152-59-8P
244152-60-1P 244152-61-2P 244152-64-5P
244152-65-6P 244152-66-7P 244152-67-8P
244152-68-9P 244152-69-0P 244152-92-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxylic acid derivs. as PPAR regulating agents)

RN 244149-61-9 CAPLUS

CN Benzenebutanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244149-62-0 CAPLUS
CN Benzenehexanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244149-63-1 CAPLUS
CN Benzenepentanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244149-71-1 CAPLUS
CN Acetic acid, [[3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244149-78-8 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244149-99-3 CAPLUS

CN Benzeneacetic acid, α,α-dimethyl-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-06-9 CAPLUS
CN Acetic acid, [[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-39-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-40-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-41-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-propylphenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-42-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-43-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(2-methylpropyl)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-44-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-48-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-49-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-50-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-51-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(3,4,5-trimethoxyphenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-52-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-53-6 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-58-1 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-61-6 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-62-7 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(3-chloro-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-63-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-64-9 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-65-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-66-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-67-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-thienyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-68-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2-furanyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-69-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-pyridinyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-70-7 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-methylphenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-71-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-72-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-73-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-74-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-75-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methyl-1,2,3-thiadiazol-5-yl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-76-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-77-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methyl-3-nitrophenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-78-5 CAPLUS
CN Benzeneacetic acid, 3-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-79-6 CAPLUS
CN Benzeneacetic acid, 3-[2-(2-cyclopentyl-5-methyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-80-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-pentylphenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-82-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(3-pyridinyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-83-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-pyridinyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-84-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methyl-1-piperazinyl)-4-thiazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-87-6 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(methylthio)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-88-7 CAPLUS
CN Benzeneacetic acid, 3-[2-(2-cyclopropyl-5-methyl-4-oxazolyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-89-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-nitrophenyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-90-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-quinolinyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-91-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[3-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244150-92-3 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[2-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 244151-00-6 CAPLUS
CN Benzenebutanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244151-01-7 CAPLUS
CN Benzenehexanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244151-02-8 CAPLUS
CN Benzenepentanoic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244151-10-8 CAPLUS
CN Acetic acid, [[3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-17-5 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244151-38-0 CAPLUS
CN Benzeneacetic acid, α,α-dimethyl-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244151-45-9 CAPLUS
CN Acetic acid, [[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-90-4 CAPLUS

CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-
(CA INDEX NAME)



RN 244151-93-7 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-
(CA INDEX NAME)



RN 244151-95-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-propylphenyl)-4-oxazolyl]ethoxy]-
(CA INDEX NAME)



RN 244151-96-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-
oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244151-97-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(2-methylpropyl)phenyl]-4-
oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244151-98-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-08-7 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-10-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-13-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-16-7 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(3,4,5-trimethoxyphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-18-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-21-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-30-5 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]- (CA INDEX NAME)



RN 244152-35-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-37-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(3-chloro-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-39-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-40-7 CAPLUS
CN Benzeneacetic acid, 3-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244152-41-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-42-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-43-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-thienyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-44-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(2-furanyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-45-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-pyridinyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-46-3 CAPLUS

CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-methylphenyl)-4-oxazolyl]ethoxy]-
(CA INDEX NAME)



RN 244152-47-4 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]-
(CA INDEX NAME)



RN 244152-48-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-
oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-49-6 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-
(CA INDEX NAME)



RN 244152-50-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]-
(CA INDEX NAME)



RN 244152-51-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methyl-1,2,3-thiadiazol-5-yl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-52-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-53-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methyl-3-nitrophenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-54-3 CAPLUS
CN Benzeneacetic acid, 3-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244152-55-4 CAPLUS
CN Benzeneacetic acid, 3-[2-(2-cyclopentyl-5-methyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244152-56-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-pentylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-59-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(3-pyridinyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-60-1 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-pyridinyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-61-2 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methyl-1-piperazinyl)-4-

thiazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-64-5 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[4-(methylthio)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-65-6 CAPLUS
CN Benzeneacetic acid, 3-[2-(2-cyclopropyl-5-methyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 244152-66-7 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-nitrophenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-67-8 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(2-quinolinyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-68-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[3-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-69-0 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-[2-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 244152-92-9 CAPLUS
CN Benzeneacetic acid, 3-[2-[5-methyl-2-(4-methyl-1-piperazinyl)-4-oxazolyl]ethoxy]-, methyl ester (CA INDEX NAME)



IT 244152-80-5P 244152-81-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carboxylic acid derivs. as PPAR regulating agents)
RN 244152-80-5 CAPLUS
CN Benzeneacetonitrile, α-hydroxy-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)

RN 244152-81-6 CAPLUS
CN Benzeneacetonitrile, α-chloro-3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:452768 CAPLUS
DOCUMENT NUMBER: 125:142746
TITLE: Oxa(thia)diazolidinediones and oxa(thia)zolidinediones as antihyperglycemic agents
INVENTOR(S): Malamas, Michael S.; Gunawan, Iwan
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 421,167. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5532256	A	19960702	US 1995-457948	19950601
US 5468762	A	19951121	US 1994-245734	19940518
PRIORITY APPLN. INFO.:			US 1994-245734	A3 19940518
			US 1995-421167	A2 19950413

OTHER SOURCE(S): MARPAT 125:142746
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to novel compds. which have demonstrated oral antihyperglycemic activity in diabetic ob/ob and db/db mice, animal models of non-insulin dependent diabetes mellitus (NIDDM or Type II diabetes). These compds. have the formula I wherein: R1 is C1-C6 alkyl, C3-C8 cycloalkyl, thienyl, furyl, pyridyl, R10C6H4 or R10C10H6 where R10 is hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, iodine, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; R2 is hydrogen or C1-C6 alkyl; X is O or S; n is 0, 1, or 2; A is II or III where R3 is hydrogen, C1-C6 alkyl, halogen, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; B is IV-VI where R4 is hydrogen, C1-C6 alkyl, allyl, C6-C10 aryl, C6-C10 aryl-(CH2)1-6, fluorine, chlorine, bromine, iodine, trimethylsilyl or C3-C8 cycloalkyl; R5 is hydrogen, C1-C6 alkyl, C6-C10 aryl, or C6-C10 aryl-(CH2)1-6; m is 0, 1, or 2; R6 is hydrogen or C1-C6 alkyl; R7 is hydrogen or C1-C6 alkyl; R8 and R9 are selected independently from hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, or iodine; Y is S; Z is N or CH; or a pharmaceutically acceptable salt thereof. Thus, alkylation of 3-hydroxylbenzaldehyde with 4-chloromethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole afforded 65% 3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]benzaldehyde; reaction of the latter with ethylmagnesium bromide followed by oxidation afforded 74% 1-{3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl}propan-1-one; condensation with tri-Et phosphonoacetate afforded 55% trans- and 28% cis-3-{3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl}pent-2-enoic acid Et ester; reduction of the trans isomer to the (E) pent-2-en-1-ol (91%) followed by condensation with BOC-HNO-BOC afforded 96% (E)-N-tert-butoxycarbonyloxy-(3-{3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl}pent-2-enyl)carbamic acid tert-Bu ester; deprotection to the hydroxylamine (88%) followed by cyclization with N-(chlorocarbonyl) isocyanate afforded 64% (E)-2-(3-{3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl}pent-2-enyl)[1,2,4]oxadiazolidine-3,5-dione VII which exhibited -76% change in blood glucose in db/db mice at 100 mg/kg p.o.
IT 174258-61-8P 174259-12-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxa(thia)diazolidinediones and oxa(thia)zolidinediones as antihyperglycemic agents)

RN 174258-61-8 CAPLUS

CN 1,2,4-Oxadiazolidine-3,5-dione, 2-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-12-2 CAPLUS

CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 174258-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(oxa(thia)diazolidinediones and oxa(thia)zolidinediones as antihyperglycemic agents)

RN 174258-60-7 CAPLUS

CN Ethanone, 1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- (CA INDEX NAME)



L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:1003034 CAPLUS
DOCUMENT NUMBER: 124:202232
TITLE: Oxazolyl azolidinediones as antihyperglycemic agents
INVENTOR(S): Malamas, Michael S.; Gunawan, Iwan
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 23 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5468762	A	19951121	US 1994-245734	19940518
CA 2190015	A1	19951123	CA 1995-2190015	19950413
WO 9531454	A1	19951123	WO 1995-US4631	19950413
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9523842	A	19951205	AU 1995-23842	19950413
AU 684357	B2	19971211		
US 5510360	A	19960423	US 1995-421111	19950413
EP 759919	A1	19970305	EP 1995-916989	19950413
EP 759919	B1	19981111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1152312	A	19970618	CN 1995-194037	19950413
HU 76823	A2	19971128	HU 1996-3185	19950413
JP 10500133	T	19980106	JP 1995-529644	19950413
AT 173256	T	19981115	AT 1995-916989	19950413
ES 2124545	T3	19990201	ES 1995-916989	19950413
ZA 9503981	A	19961118	ZA 1995-3981	19950516
US 5532256	A	19960702	US 1995-457948	19950601

PRIORITY APPLN. INFO.: US 1994-245734 A 19940518
US 1995-421167 A2 19950413
WO 1995-US4631 W 19950413

OTHER SOURCE(S): MARPAT 124:202232
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to compds. which have oral antihyperglycemic activity of the formula I wherein: R1 is, e.g., C1-C6 alkyl, C3-C8 cycloalkyl, thienyl, furyl, pyridyl, R10-substituted Ph or naphthyl where R10 is hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, iodine, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; R2 is hydrogen or C1-C6 alkyl; X is O or S; n is 1 or 2; A is II or III where R3 is hydrogen, C1-C6 alkyl, halogen, C1-C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; B is IV, V, or VI where R4 is hydrogen, C1-C6 alkyl, allyl, C6-C10 aryl, C6-C10-aryl-(CH2)1-6, fluorine, chlorine, bromine, iodine, trimethylsilyl or C3-C8 cycloalkyl; R5 is hydrogen, C1-C6 alkyl, C6-C10 aryl, or C6-C10-aryl-(CH2)1-6 ; x is 0, 1, or 2; R6 is hydrogen or C1-C6 alkyl; R7 is hydrogen or C1-C6 alkyl; R8 and R9 are selected independently from hydrogen, C1-C6 alkyl, fluorine, chlorine, bromine, or iodine; Y is O or S; Z is N or CH when Y is O and Z is CH when Y is S; or a pharmaceutically

acceptable salt thereof. Thus, e.g., treatment of (E)-N-(3-{3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl}pent-2-enyl)hydroxylamine (preparation given) with N-(Chlorocarbonyl)isocyanate afforded 64% (E)-2-(3-{3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl}pent-2-enyl)[1,2,4]oxadiazolidine-3,5-dione (VII) which exhibited -76% change in blood glucose in diabetic db/db mice at 100 mg/kg p.o.

IT 174258-61-8P 174259-12-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxazolyl azolidinediones as antihyperglycemic agents)

RN 174258-61-8 CAPLUS

CN 1,2,4-Oxadiazolidine-3,5-dione, 2-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 174259-12-2 CAPLUS

CN 2,4-Oxazolidinedione, 5-[(2E)-3-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 174258-60-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(oxazolyl azolidinediones as antihyperglycemic agents)

RN 174258-60-7 CAPLUS

CN Ethanone, 1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- (CA INDEX NAME)



L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:983209 CAPLUS

DOCUMENT NUMBER: 124:105587

TITLE: Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of 5-Lipoxygenase

AUTHOR(S): Malamas, Michael S.; Carlson, Richard P.; Grimes, David; Howell, Ralph; Glaser, Keith; Gunawan, Iwan; Nelson, James A.; Kanzelberger, Mira; Shah, Uresh; Hartman, David A.

CORPORATE SOURCE: Wyeth-Ayerst Research Inc., Princeton, NJ, 08543-8000, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(1), 237-45
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:105587

AB Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO) inhibitors. Structure-activity relations studies have demonstrated that electroneg. substituents on the 2-Ph portion of the oxazole tail increased the ex vivo potency of these inhibitors. Similar substitutions on the thiazole analogs had only minor contribution to the ex vivo activity. The trifluoromethyl-substituted oxazole was the best compound of the oxazole series in both the ex vivo (6-h pretreated rats) and in vivo (3-h pretreated rats) RPAR assay with ED50 values of approx. 1 and 3.6 mg/kg, resp., but was weakly active in the allergic guinea pig assay. An unsubstituted thiazole was the best compound of the thiazole series, by inhibiting the leukotriene B4 biosynthesis in the RPAR assay (3-h pretreated rats) by 99%, at an oral dose of 10 mg/kg, and the bronchoconstriction in the allergic guinea pig by 50%, at an i.v. dose of 10 mg/kg. This activity was selective for 5-LO, as concns. up to 15 μM in mouse macrophages did not affect prostaglandin formation. One of the oxazoles was the most active inhibitor in the human monocyte assay with an IC50 value of 7 nM.

IT 166262-09-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(azole phenoxy hydroxyureas as lipoxygenase inhibitors)

RN 166262-09-5 CAPLUS

CN Urea, N-hydroxy-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)



L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:705727 CAPLUS
DOCUMENT NUMBER: 123:112070
TITLE: Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents
INVENTOR(S): Malamas, Michael S.; Gunawan, Iwan
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 14 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5428048	A	19950627	US 1993-148602	19931108
US 5541205	A	19960730	US 1995-409781	19950324
PRIORITY APPLN. INFO.:			US 1993-148602	A3 19931108

OTHER SOURCE(S): CASREACT 123:112070; MARPAT 123:112070
GI


I


II


III


IV

AB A method of inhibiting the biosynthesis of leukotrienes and the oxidative modification of lipids is claimed, which comprises administration to a mammal in need thereof a therapeutically effective amount of aryl-N-hydroxyureaa I wherein: R2 is hydrogen, halogen or C1-C6 alkyl; one of R3 and R4 is H and the other is CHR5N(OH)C(:Y)R, Y is O or S; R5 is hydrogen or Me, R6 is NH2, CH3 or OCH3; and R1 is II, III, or IV wherein R7, R8 and R10 are independently halogen, trifluoromethyl, alkyl, alkoxy, methanesulfonyl or trifluoromethanesulfonyl; R9 is hydrogen or methyl; and Z is O or S, or a pharmaceutically acceptable salt thereof. Thus, e.g., to a solution of 4-(2'-hydroxyethyl)-5-methyl-2-phenyloxazole (III-CH2CH2OH, R8 = H, R9 = Me, Z = O) and 4-HOC6H4CHO in THF was added di-Et azodicarboxylate; workup afforded 4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde (78%); oximation (90%), followed by reduction to the hydroxylamine (85%) and carbamoylation with trimethylsilyl isocyanate afforded 1-hydroxy-1-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]urea I [R1 = III, R8 = H, R9 = Me, Z = O, R2 = R3 = H, R4 = CH2N(OH)CONH2; 69%] which demonstrated inhibition of 5-lipoxygenase in human whole blood with 55% inhibition of LTB4 at 1μM dose and inhibited Cu+2-mediated oxidation of low d. lipoprotein with IC50 = 0.69 μM.

IT 166262-09-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)

RN 166262-09-5 CAPLUS

CN Urea, N-hydroxy-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 16:56:48 ON 07 MAR 2008)

     FILE 'REGISTRY' ENTERED AT 16:56:58 ON 07 MAR 2008
L1             STRUCTURE UPLOADED
L2            17 S L1
L3           318 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 16:57:26 ON 07 MAR 2008
L4            24 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    142.80     321.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -19.20     -19.20

STN INTERNATIONAL LOGOFF AT 17:12:14 ON 07 MAR 2008
```